Project description
Better liver cancer treatment and management
Liver cancer, affecting approximately 1 million individuals annually worldwide, is a health challenge, with Europe witnessing around 90 000 new cases each year. It is the third leading cause of cancer-related mortality globally. Hepatocellular carcinoma (HCC) and hepatoblastoma (HB), especially, present complex treatment hurdles due to their poorly understood characteristics. In this context, the EU-funded THRIVE project addresses this crisis with a multidisciplinary approach that brings together 13 partners across eight countries. Using cutting-edge technologies like single-cell RNASeq and AI, THRIVE aims to understand at-risk populations, tumour biology, and treatment resistance. By analysing 6 700 samples from 15 patient cohorts, THRIVE seeks to develop biomarkers for current therapies and affordable novel treatments.
Objective
"Liver cancer is a major health problem with ~1 million cases diagnosed each year (~90,000 cases/year in Europe), and it is the 3rd cause of cancer-related mortality worldwide. Hepatocellular carcinoma (HCC) in adults, and hepatoblastoma (HB) in children are considered poorly understood cancers. HCC is a difficult-to-cure cancer (curation rate ~ 30%) with poor outcome (median survival < 2 years in advanced stages), due to limited understanding of at-risk populations, resistance to therapies and lack of precision oncology. In HB, outcomes are hampered in one fourth of cases due disease progression after surgical intervention and adjuvant chemotherapy.
THRIVE aims by to improve the outcome of both paediatric and adult liver cancer patients by understanding at-risk populations, tumour-host interactions, and by developing biomarkers for current therapies and novel, affordable treatments to overcome resistance. THRIVE brings together a strong, multidisciplinary team -13 partners, from 8 countries- with complementary expertise to leverage cutting-edge technologies (single-cell RNASeq, spatial transcriptomics, microbiota analysis, artificial intelligence, mouse models and patient-derived organoids) and sectors (i.e academia, SMEs, hospitals, patient associations) and 15 patient cohorts (~6,700 samples).
THRIVE expects to: 1) Define molecular features of cancer predisposition and at-risk populations for development of liver cancer. 2) Develop a complete human liver cancer blueprint of tumour, immune, stromal cells and intra-tumoral microbiomes. 3) Identify AI-based and molecular markers of response to treatments. 4) Implement a preclinical drug testing platform for discovery of affordable therapies with high social impact. 5) Maximize the impact in the European society by integrating SSH disciplines, delivering accessible and re-usable data and tools to support EU initiatives such as the UNCAN.eu platform, and by influencing policymakers and health professionals.
This action is part of the Cancer Mission cluster of projects on “Understanding (tumour-host interactions)""."
Fields of science
Keywords
Programme(s)
- HORIZON.2.1 - Health Main Programme
Funding Scheme
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinator
08036 Barcelona
Spain